Introduction
Rematib Tablet (Extended Release) 15 mg is an oral Janus kinase (JAK) inhibitor used primarily in the treatment of various autoimmune diseases. It is designed to modulate the immune response by selectively targeting specific JAK pathways, which play a crucial role in the inflammatory process.
Uses
Rematib Tablet (Extended Release) 15 mg is used for:
- Treatment of moderate to severe rheumatoid arthritis in adults who have not responded adequately to methotrexate or other disease-modifying antirheumatic drugs (DMARDs)
- Treatment of active psoriatic arthritis in adults
- Management of moderate to severe atopic dermatitis in adults and pediatric patients (aged 12 years and older) when topical therapies are inadequate
| Brand Name | Rematib |
|---|---|
| Type | Tablet (Extended Release) |
| Weight | 15 mg |
| Generic | Upadacitinib |
| Manufacturer | Drug International Ltd. |
| Available in | English বাংলা |
Mechanism of Action
Rematib Tablet (Extended Release) 15 mg works by inhibiting Janus kinases (JAKs), specifically JAK1, which are involved in the signaling pathways that mediate inflammatory responses. By blocking JAK1, Rematib Tablet (Extended Release) 15 mg reduces the activity of pro-inflammatory cytokines, leading to a decrease in inflammation and improvement in symptoms associated with autoimmune diseases.
How Long Does It Take to Work?
Patients may begin to notice improvements in symptoms within 1-2 weeks of starting Rematib Tablet (Extended Release) 15 mg, although it may take several weeks to achieve maximal therapeutic benefits. The time to onset of action can vary based on the condition being treated and individual patient factors.
Absorption
Rematib Tablet (Extended Release) 15 mg is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1-4 hours. The presence of food does not significantly affect the absorption of Rematib Tablet (Extended Release) 15 mg, making it flexible for administration with or without meals.
Route of Elimination
Rematib Tablet (Extended Release) 15 mg is primarily metabolized in the liver through oxidative pathways involving cytochrome P450 enzymes, particularly CYP3A4. It is excreted mainly through the feces, with a minor portion excreted in the urine. The drug's metabolic profile contributes to its overall clearance and efficacy.
Dosage
The recommended dose of Upadacitinib is 15 mg once daily. Upadacitinib may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. Avoid initiation or interrupt Upadacitinib if absolute lymphocyte count is less than 500 cells/mm3, absolute neutrophil count is less than 1000 cells/mm3 or hemoglobin level is less than 8 g/dL.Pediatric Use: The safety and efficacy of Upadacitinib in children and adolescents aged 0 to 18 years have not yet been established. No data are available.
Hepatic Impairment: Upadacitinib is not recommended in patients with severe hepatic impairment.
The typical dosage for Rematib Tablet (Extended Release) 15 mg is 15 mg taken orally once daily. For certain indications, such as rheumatoid arthritis, the dosage may be adjusted based on the patient's response and tolerability. Dosage adjustments may be necessary in cases of hepatic impairment or when used concomitantly with strong CYP3A4 inhibitors.
Administration
Administer Rematib Tablet (Extended Release) 15 mg as a single oral tablet daily. It can be taken with or without food. Consistent daily dosing at the same time helps maintain stable drug levels and optimize therapeutic effects.
Side Effects
Common side effects include:
- Upper respiratory tract infections
- Headache
- Diarrhea
- Nausea
- Elevated liver enzymes
Toxicity
Toxicity symptoms may include severe infections, elevated liver enzymes, or significant changes in blood cell counts. In case of suspected toxicity, discontinue Rematib Tablet (Extended Release) 15 mg and seek medical attention. Management includes supportive care and appropriate medical intervention based on the severity of symptoms.
Precautions
Precautions include:
- Monitoring for signs of infection due to immunosuppressive effects
- Regular liver function tests to detect hepatotoxicity
- Assessing blood cell counts periodically to identify potential hematologic issues
Interaction
Rematib Tablet (Extended Release) 15 mg may interact with other medications, particularly those affecting hepatic enzyme systems (e.g., CYP3A4 inhibitors or inducers). Inform healthcare providers of all current medications to manage interactions and adjust dosages as needed.
Disease Interaction
Use with caution in patients with a history of tuberculosis, hepatitis, or other chronic infections. Adjustments or alternative treatments may be required based on the patient’s disease status and concurrent conditions.
Drug Interaction
Potential drug interactions include those with medications that alter CYP3A4 activity. Concomitant use with strong CYP3A4 inhibitors or inducers may require dose adjustments of Rematib Tablet (Extended Release) 15 mg. Consult healthcare providers for managing and monitoring drug interactions.
Food Interactions
Food does not significantly affect the absorption or efficacy of Rematib Tablet (Extended Release) 15 mg. It can be taken with or without food, allowing flexibility in the dosing schedule.
Pregnancy Use
Rematib Tablet (Extended Release) 15 mg is not recommended during pregnancy due to potential risks to the fetus. Effective contraception should be used during treatment, and alternative therapies should be considered for pregnant patients.
Lactation Use
The safety of Rematib Tablet (Extended Release) 15 mg during lactation is not well-established. It is advisable to avoid breastfeeding while on this medication due to potential risks to the infant. Consult healthcare providers for appropriate alternatives if breastfeeding.
Acute Overdose
Acute overdose may lead to exacerbated side effects such as severe infections or liver dysfunction. In case of overdose, seek immediate medical attention to manage symptoms and provide appropriate treatment.
Contraindication
Contraindications include known hypersensitivity to Rematib Tablet (Extended Release) 15 mg or any component of the formulation, active or recent serious infections, and severe hepatic impairment. Ensure that these conditions are evaluated before initiating therapy.
Use Direction
Administer Rematib Tablet (Extended Release) 15 mg as prescribed. Take one tablet orally once daily, at the same time each day, with or without food. Adhere to the prescribed regimen for optimal results and to minimize potential side effects.
Storage Conditions
Store Rematib Tablet (Extended Release) 15 mg at room temperature, away from moisture and heat. Keep it in its original container and ensure it is out of reach of children. Proper storage helps maintain the medication's effectiveness and safety.
Volume of Distribution
The volume of distribution for Rematib Tablet (Extended Release) 15 mg reflects its distribution throughout body tissues. Specific values are provided in detailed pharmacokinetic studies, indicating how extensively the drug is distributed in the body.
Half Life
The half-life of Rematib Tablet (Extended Release) 15 mg is approximately 9-14 hours. This value influences the dosing schedule and helps maintain effective drug levels throughout the treatment period.
Clearance
Rematib Tablet (Extended Release) 15 mg is cleared primarily through hepatic metabolism and subsequent fecal excretion. The clearance rate is influenced by liver function and potential interactions with other medications.
See in details version Rematib Tablet (Extended Release) 15 mg also Rematib Tablet (Extended Release) 15 mg in bangla
Social card
Some Frequently Asked Questions About Rematib Tablet (Extended Release) 15 mg
